---
document_datetime: 2025-08-12 12:04:13
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/naveruclif-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: naveruclif-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.0828185
conversion_datetime: 2025-12-28 14:46:45.080418
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Naveruclif

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.II.f.1.b Extension of the shelf life of the | 11/08/2025                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000287045      | finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |                   |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IA_IN / | This was an application for a group of variations. B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) | 04/08/2025 | N/A | EMA/VR/0000290057 |

<div style=\"page-break-after: always\"></div>

|                                       | affect the properties of the finished product - Accepted B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product - Accepted B.V.a.1 Inclusion of a new, updated or amended Plasma Master File in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - B.V.a.1.d Inclusion of an updated/amended Plasma Master File when changes do not affect the properties of the finished product -   |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000279697 | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (IB) - To update section 4.6 of the SmPC based on the Reproductive Toxicity                                                                                                                                                                                                                                      | 27/06/2025 | SmPC and PL | To update section 4.6 of the SmPC based on the Reproductive Toxicity Testing and Labeling recommendations, Food and Drug Administration Guidance (May 2019) and the Non-clinical Working Party/Non-clinical Working Party (S/Nc), European Medicines Agency recommendations (March 2023) on the duration of contraception following the end of treatment with a genotoxic drug. The Package Leaflet is updated accordingly. The change follows assessment of the same change for the reference |

<div style=\"page-break-after: always\"></div>

|                                          | Testing and Labeling recommendations, Food and Drug Administration Guidance (May 2019) and the Non-clinical Working Party/Non-clinical Working Party (S/Nc), European Medicines Agency recommendations (March 2023) on the duration of contraception following the end of treatment with a genotoxic drug. The Package Leaflet is updated accordingly. The change follows assessment of the same change for the reference product, Abraxane.   |            |     | product, Abraxane.   |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------|
| Variation type IB / EMA/VR/0000277911    | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                                                                                                                                                                              | 20/06/2025 | N/A |                      |
| Variation type IA_IN / EMA/VR/0000276235 | This was an application for a group of variations. B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.1 New certificate from an already approved manufacturer - Accepted B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.3 New certificate from a new manufacturer (replacement or                                        | 16/06/2025 | N/A |                      |

<div style=\"page-break-after: always\"></div>

|                                          | addition) - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     |                 |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|
| Variation type IA_IN / EMA/VR/0000258150 | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.2 Including batch control/testing - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted | 12/03/2025 | N/A | Annex II and PL |

<div style=\"page-break-after: always\"></div>

| A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|